Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DYNNASDAQ:GHRSNASDAQ:JANXNASDAQ:RNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$23.84-4.6%$26.05$6.40▼$30.27$2.05B0.951.96 million shs289,360 shsGHRSGH Research$10.53-5.0%$9.92$5.05▼$14.64$547.88M0.84131,767 shs19,100 shsJANXJanux Therapeutics$46.52-3.5%$37.62$5.65▼$58.69$2.40B4.18749,410 shs280,245 shsRNAAvidity Biosciences$23.92-4.7%$21.74$4.82▼$27.66$1.91B0.781.16 million shs531,862 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics-1.81%+0.64%-4.14%+39.55%+134.77%GHRSGH Research-1.95%+0.82%+5.02%+61.05%+40.25%JANXJanux Therapeutics-3.15%+0.52%+25.12%+401.14%+225.74%RNAAvidity Biosciences-0.20%+6.54%+8.19%+139.64%+49.08%The Next Nvidia? (Ad)The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYNDyne Therapeutics3.1707 of 5 stars4.61.00.00.01.24.20.6GHRSGH Research1.4524 of 5 stars3.51.00.00.02.32.50.0JANXJanux Therapeutics3.6554 of 5 stars4.54.00.00.02.63.30.0RNAAvidity Biosciences1.0621 of 5 stars3.51.00.00.02.70.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics3.14Buy$37.4357.00% UpsideGHRSGH Research3.00Buy$39.50275.12% UpsideJANXJanux Therapeutics3.00Buy$61.3331.84% UpsideRNAAvidity Biosciences3.00Buy$36.3351.90% UpsideCurrent Analyst RatingsLatest DYN, JANX, RNA, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024JANXJanux TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/11/2024RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/21/2024JANXJanux TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.003/20/2024JANXJanux TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$100.003/14/2024RNAAvidity BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$60.003/13/2024JANXJanux TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $48.003/11/2024JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$53.003/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$4.94 per shareN/AJANXJanux Therapeutics$8.08M297.43N/AN/A$7.46 per share6.24RNAAvidity Biosciences$9.56M199.47N/AN/A$6.76 per share3.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)GHRSGH Research-$35.59M-$0.68N/AN/AN/AN/A-15.48%-15.01%5/9/2024 (Estimated)JANXJanux Therapeutics-$58.29M-$1.34N/AN/AN/A-721.18%-17.88%-15.95%5/14/2024 (Estimated)RNAAvidity Biosciences-$212.22M-$2.90N/AN/AN/A-2,219.87%-39.74%-34.98%5/14/2024 (Estimated)Latest DYN, JANX, RNA, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023JANXJanux Therapeutics-$0.37-$0.25+$0.12-$0.25$0.98 million$2.46 million3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/A2/29/2024Q4 2023GHRSGH Research-$0.20-$0.21-$0.01-$0.21N/AN/A2/28/2024Q4 2023RNAAvidity Biosciences-$0.54-$0.79-$0.25-$0.79$32.08 million$2.19 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne TherapeuticsN/A2.532.53GHRSGH ResearchN/A24.4924.49JANXJanux TherapeuticsN/A26.8026.80RNAAvidity BiosciencesN/A7.587.58OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%GHRSGH Research56.90%JANXJanux Therapeutics75.39%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics20.77%GHRSGH Research41.60%JANXJanux Therapeutics35.40%RNAAvidity Biosciences2.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics14186.18 million68.28 millionOptionableGHRSGH Research4952.03 million30.38 millionOptionableJANXJanux Therapeutics6451.66 million33.37 millionOptionableRNAAvidity Biosciences25379.72 million78.13 millionOptionableDYN, JANX, RNA, and GHRS HeadlinesSourceHeadlineArthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stockinsidertrades.com - April 23 at 4:24 AMInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of Stockmarketbeat.com - April 22 at 6:57 PMAvidity Biosciences (NASDAQ:RNA) Stock Price Up 6.5%marketbeat.com - April 22 at 4:46 PMAvidity Biosciences gets grant for polynucleic acid conjugate for treating FSHD through rna interferencepharmaceutical-technology.com - April 22 at 8:52 AMMirae Asset Global Investments Co. Ltd. Has $1.50 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 22 at 4:31 AMRaymond James & Associates Increases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 21 at 4:01 AMRaymond James Financial Services Advisors Inc. Raises Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 17 at 4:11 AMUnveiling the key role of RNA modification in HIV-1 survival and replicationmsn.com - April 13 at 8:29 AMVanguard Group Inc. Acquires 47,305 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 13 at 4:31 AMAnalysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)markets.businessinsider.com - April 11 at 1:39 PMSG Americas Securities LLC Invests $377,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 8 at 4:09 AMArthur A. Levin Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stockinsidertrades.com - April 5 at 5:04 AMAvidity Biosciences (NASDAQ:RNA) Shares Down 2.7% Following Insider Sellingmarketbeat.com - April 4 at 11:55 AMInsider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Sharesfinance.yahoo.com - April 4 at 11:11 AMAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 20,000 Sharesmarketbeat.com - April 3 at 9:19 PMAvidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $26.62marketbeat.com - April 1 at 5:51 PMAvidity Biosciences gets grant for treatment of muscle atrophy or myotonic dystrophy using sirnapharmaceutical-technology.com - March 29 at 8:51 AMAvidity Biosciences to Participate in Upcoming Investor Conferencesprnewswire.com - March 27 at 9:00 AMRNA Apr 2024 17.500 callfinance.yahoo.com - March 17 at 5:14 AMRNA Apr 2024 17.500 putfinance.yahoo.com - March 16 at 12:35 PMAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $980,800.00 in Stockinsidertrades.com - March 16 at 8:42 AMRNA Apr 2024 22.500 callfinance.yahoo.com - March 16 at 2:35 AMInsider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)finance.yahoo.com - March 15 at 9:34 PMAvidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $608,931.23 in Stockinsidertrades.com - March 13 at 6:40 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHigher Oil Prices Could Give NextEra’s Stock Earnings a BoostApril 24, 2024 10:40 AMView Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost3 Stocks About to Book Gains on Building Products DemandApril 4, 2024 1:07 PMView 3 Stocks About to Book Gains on Building Products DemandKrispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?March 28, 2024 8:43 AMView Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?Is a Children’s Place Turnaround in the Cards? April 2, 2024 8:00 AMView Is a Children’s Place Turnaround in the Cards? Cannabis: One Stock to Play the MovementApril 8, 2024 8:38 AMView Cannabis: One Stock to Play the MovementAll Headlines Company DescriptionsDyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.GH ResearchNASDAQ:GHRSGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Janux TherapeuticsNASDAQ:JANXJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Avidity BiosciencesNASDAQ:RNAAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.